ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 292 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.07 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $191,000 | -25.7% | 5,781 | -20.8% | 0.01% | -12.5% |
| Q2 2022 | $257,000 | +15.2% | 7,302 | +50.6% | 0.01% | +60.0% |
| Q1 2022 | $223,000 | -39.6% | 4,848 | -12.9% | 0.01% | -37.5% |
| Q4 2021 | $369,000 | +7.0% | 5,566 | +0.7% | 0.01% | 0.0% |
| Q3 2021 | $345,000 | -27.8% | 5,530 | -4.2% | 0.01% | -11.1% |
| Q2 2021 | $478,000 | +32.0% | 5,770 | +5.7% | 0.01% | +28.6% |
| Q1 2021 | $362,000 | -14.0% | 5,460 | -0.5% | 0.01% | -22.2% |
| Q4 2020 | $421,000 | +78.4% | 5,490 | 0.0% | 0.01% | +80.0% |
| Q3 2020 | $236,000 | -0.4% | 5,490 | 0.0% | 0.01% | -16.7% |
| Q2 2020 | $237,000 | +48.1% | 5,490 | -1.4% | 0.01% | +50.0% |
| Q1 2020 | $160,000 | -55.4% | 5,568 | -1.5% | 0.00% | -50.0% |
| Q4 2019 | $359,000 | +120.2% | 5,653 | -2.4% | 0.01% | +100.0% |
| Q3 2019 | $163,000 | +5.2% | 5,793 | -0.9% | 0.00% | +33.3% |
| Q2 2019 | $155,000 | -71.4% | 5,843 | -92.1% | 0.00% | -72.7% |
| Q3 2016 | $542,000 | – | 73,686 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |